Reportable Segments (Tables)

9 Months Ended

Apr. 30, 2020

Segment Reporting [Abstract]

Information as to reportable segments

Information as to reportable segments is summarized below

	Three Months Ended April 30,				Nine Months Ended April 30,
Net sales	2020		2019		2020		2019
Medical	$	101,222	$	130,722	$	365,534	$	386,854
Life Sciences	48,189		44,975		147,452		147,333
Dental	79,170		45,131		247,457		120,548
Dialysis	8,352		7,724		22,234		23,944
Total net sales	$	236,933	$	228,552	$	782,677	$	678,679

	Three Months Ended April 30,				Nine Months Ended April 30,
Income from operations	2020		2019		2020		2019
Medical	$	6,153	$	24,302	$	48,806	$	75,038
Life Sciences	5,786		4,091		20,621		16,364
Dental	1,549		5,509		5,697		17,703
Dialysis	1,859		1,151		4,988		3,728
	15,347		35,053		80,112		112,833
General corporate expenses(1)	(7,097)		20,241		35,648		44,147
Total income from operations	$	22,444	$	14,812	$	44,464	$	68,686

_______________________________________________

(1)Includes fair value adjustments for contingent consideration arrangements related to the Hu-Friedy acquisition.